Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer

(2016) Sara Alkner et al.   PLoS One

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy

(2015) Sara Alkner et al.   EUROPEAN JOURNAL OF CANCER

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Hypoxia-inducible factor 1α in breast cancer prognosis

(2013) Wei Wang et al.   CLINICA CHIMICA ACTA

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer

(2012) Maria E. C. Sandberg et al.   BREAST CANCER RESEARCH AND TREATMENT

Prediction of outcome after diagnosis of metachronous contralateral breast cancer

(2011) Sara Alkner et al.   BMC CANCER

AIB1 is a predictive factor for tamoxifen response in premenopausal women

(2009) S. Alkner et al.   ANNALS OF ONCOLOGY

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

(2009) G L Semenza   ONCOGENE

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

(2008) Thomas Frogne et al.   BREAST CANCER RESEARCH AND TREATMENT

Hypoxia-Inducible Factor-2  Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer

(2008) K. Helczynska et al.   CANCER RESEARCH